Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Ashina M, Mitsikostas DD, Ramirez Campos V, Barash S, Ning X, Diener HC. Ashina M, et al. Among authors: barash s. Headache. 2023 Nov-Dec;63(10):1351-1358. doi: 10.1111/head.14651. Epub 2023 Nov 13. Headache. 2023. PMID: 37955395 Clinical Trial.
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR. Geva M, et al. Among authors: barash s. Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27. Hum Mol Genet. 2016. PMID: 27466197 Free PMC article.
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, Kessler Y, Janka L, Diener HC. Ashina M, et al. Among authors: barash s. J Headache Pain. 2021 Jul 10;22(1):68. doi: 10.1186/s10194-021-01279-7. J Headache Pain. 2021. PMID: 34246226 Free PMC article. Clinical Trial.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC. Spierings ELH, et al. Among authors: barash s. Headache. 2021 Oct;61(9):1376-1386. doi: 10.1111/head.14196. Epub 2021 Aug 10. Headache. 2021. PMID: 34374086 Free PMC article. Clinical Trial.
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020.
Barash S, Ramirez Campos V, Ning X, Driessen MT, Krasenbaum LJ, Carr K, Cohen JM. Barash S, et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 Nov;394(11):2343-2346. doi: 10.1007/s00210-021-02156-5. Epub 2021 Sep 28. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34581836 Free PMC article.
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A, Terwindt GM, Cohen JM, Barash S, Campos VR, Galic M, Ning X, Kärppä M. MaassenVanDenBrink A, et al. Among authors: barash s. J Headache Pain. 2021 Dec 18;22(1):152. doi: 10.1186/s10194-021-01336-1. J Headache Pain. 2021. PMID: 34922436 Free PMC article. Clinical Trial.
51 results